MAGEA9 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-17884
Key Product Details
Species Reactivity
Human
Applications
Immunocytochemistry/ Immunofluorescence
Label
Unconjugated
Antibody Source
Polyclonal Rabbit IgG
Concentration
Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
This antibody was developed against Recombinant Protein corresponding to amino acids: SAAGSSSPPQSPQGGASSSISVYYT
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Scientific Data Images for MAGEA9 Antibody
Immunocytochemistry/ Immunofluorescence: MAGEA9 Antibody [NBP3-17884]
Immunocytochemistry/Immunofluorescence: MAGEA9 Antibody [NBP3-17884] - Staining of human cell line RT4 shows localization to nucleoplasm.Applications for MAGEA9 Antibody
Application
Recommended Usage
Immunocytochemistry/ Immunofluorescence
0.25-2 ug/ml
Application Notes
Immunocytochemistry/Immunofluorescence, PFA/Triton X-100 is recommended for fixation/permeabilization.
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, pH 7.2, 40% glycerol
Preservative
0.02% Sodium Azide
Concentration
Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: MAGEA9
Alternate Names
Cancer/testis antigen 1.9, CT1.9MAGEA9B, MAGE-9 antigen, MAGE9cancer/testis antigen family 1, member 9, MAGEA9A, melanoma antigen family A, 9, melanoma-associated antigen 9, MGC8421
Gene Symbol
MAGEA9
Additional MAGEA9 Products
Product Documents for MAGEA9 Antibody
Product Specific Notices for MAGEA9 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...